報價延遲最少15分鐘:2025/06/03 19:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.52 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.19/-1.78
|
|
企業價值
22.14M
|
| 資產負債 |
|
每股賬面淨值
1.73
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
6.59M
|
|
每股收益
0.84
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/03 19:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. |